StockData
ADARx Pharmaceuticals, Inc. logo

ADARx Pharmaceuticals, Inc. (ADRX) company profile

ADRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Last filing: 10-Q on Nov 12, 2026
$13.82−0.18 (-1.29%)

Close on Nov 17, 2026Market cap $1.48BP/E –Yield –

About ADARx Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

ADARx Pharmaceuticals, Inc. is listed on Nasdaq under the ticker ADRX, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31.

Company profile

Company

Legal name
ADARx Pharmaceuticals, Inc.
Headquarters
San Diego, CA
Address
5871 Oberlin Drive, Suite 200 92121
Phone
(858) 283-9472
Website
adarx.com
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
ADRX
Exchange
Nasdaq
IPO date
Sep 28, 2026
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1802369
CUSIP
00654F105
ISIN
US00654F1057
FIGI
BBG00WHNQV30
Share class FIGI
BBG00WHNQV49
EIN
84-4145188

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Zhen LiPresident and CEO, Director5,861,199
Rui (NMN) ZhuChief Technology Officer2,511,943
Ryan FiskCFO and CBO–
Robert William AcklesChief People Officer–
Alan Robert MacLeodChief Scientific Officer–
Capital GP VII LLC OrbiMedDirector–
Advisors Llc OrbimedDirector–
Carl L. GordonDirector7,127,019
Advisors Israel II Ltd OrbiMedDirector–
Erez ChimovitsDirector8,974,061
Genesis GP LLC OrbiMedDirector588,235
OrbiMed Israel GP II, L.P.Director–
Simeon GeorgeDirector7,133,690
Ying HuangDirector–
Mary TagliaferriDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 28, 2026
Offer price
$17.00
Securities offered
26,250,000
Gross proceeds
$446.25M
Exchange
Nasdaq
First trading day
Sep 25, 2026
First-day close
$19.35+13.8%
Lock-up ends (est.)
Mar 24, 2027

“The initial public offering price is $17.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?